The influence of polycystic ovary syndrome and metabolic syndrome on the choice of the type of delivery: literature review
DOI:
https://doi.org/10.36557/2674-8169.2023v5n5p4035-4045Keywords:
Metabolic Syndrome, Polycystic Ovary Syndrome, Type of delivery, PregnancyAbstract
Introduction: Polycystic Ovary Syndrome (PCOS) and Metabolic Syndrome (MS) are interconnected through various physiological pathways, and their coexistence may have significant implications, especially during pregnancy and the childbirth process. During pregnancy, women with PCOS and MS may face an increased risk of obstetric complications. Regarding the impact on childbirth, PCOS and MS can influence the choice of the type of delivery.
Methodology: This work constitutes a literature review, following the systematization with the five pillars described below. 1) Problem statement: "What is the influence of PCOS and MS on the choice of the type of delivery?". 2) Relevant studies were identified using the PUBMED platform with the descriptors "Metabolic Syndrome, Polycystic Ovary Syndrome, Parturition, Pregnancy," PUBMED all in accordance with MESH. 3) Initially, 11 studies were selected; 4 were discarded after a thorough reading as they did not contribute to the problem statement. 4) Data extraction was performed using a text editing program. 5) Experts were consulted.
Results: The studies revealed that PCOS and MS are associated with a clinically significant increase in the risk of complications during pregnancy compared to control groups. Additionally, there is a 3 to 4 times higher likelihood of developing pregnancy-induced hypertension and preeclampsia, a threefold increase in the risk of gestational diabetes, and a twofold likelihood of premature birth. The elevated obstetric risk for women with PCOS is reflected in a higher rate of spontaneous abortion. Moreover, it was observed that, compared to the general population, PCOS and MS are more associated with cesarean delivery.
Conclusion: Cesarean delivery is predominant in patients with PCOS and MS. Furthermore, there is a higher risk of developing pregnancy-induced hypertension, preeclampsia, and premature birth.
Downloads
References
Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015 Sep-Oct;21(5):575-92. doi: 10.1093/humupd/dmv029. Epub 2015 Jun 27. PMID: 26117684. Disponível: https://pubmed.ncbi.nlm.nih.gov/26117684/.
Palomba S, Falbo A, Daolio J, Battaglia FA, La Sala GB. Pregnancy complications in infertile patients with polycystic ovary syndrome: updated evidence. Minerva Ginecol. 2018 Dec;70(6):754-760. doi: 10.23736/S0026-4784.18.04230-2. Epub 2018 Apr 11. PMID: 29644330. Disponível: https://pubmed.ncbi.nlm.nih.gov/29644330/.
Mills G, Badeghiesh A, Suarthana E, Baghlaf H, Dahan MH. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod. 2020 Jul 1;35(7):1666-1674. doi: 10.1093/humrep/deaa099. PMID: 32535629. Disponível: https://pubmed.ncbi.nlm.nih.gov/32535629/.
Foroozanfard F, Asemi Z, Bazarganipour F, Taghavi SA, Allan H, Aramesh S. Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study. Gynecol Endocrinol. 2020 Jan;36(1):61-65. doi: 10.1080/09513590.2019.1631278. Epub 2019 Jul 2. PMID: 31264483. Disponível: https://pubmed.ncbi.nlm.nih.gov/31264483/
Tosti G, Barberio A, Tartaglione L, Rizzi A, Di Leo M, Viti L, Sirico A, De Carolis S, Pontecorvi A, Lanzone A, Pitocco D. Lights and shadows on the use of metformin in pregnancy: from the preconception phase to breastfeeding and beyond. Front Endocrinol (Lausanne). 2023 Jun 20;14:1176623. doi: 10.3389/fendo.2023.1176623. PMID: 37409227; PMCID: PMC10319127. Disponível: https://pubmed.ncbi.nlm.nih.gov/37409227/
Hart R. Generational Health Impact of PCOS on Women and their Children. Med Sci (Basel). 2019 Mar 18;7(3):49. doi: 10.3390/medsci7030049. PMID: 30889922; PMCID: PMC6473601. Disponível: https://pubmed.ncbi.nlm.nih.gov/30889922/.
Shaaban Z, Tamadon A, Jafarzadeh Shirazi MR, Zamiri MJ, Derakhshanfar A. Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats. Iran J Basic Med Sci. 2022 Jan;25(1):110-120. doi: 10.22038/IJBMS.2022.60962.13499. PMID: 35656443; PMCID: PMC9118272. Disponível: https://pubmed.ncbi.nlm.nih.gov/35656443/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Luciana Shiguemi Yamada, Hosana Maria Araújo Rêgo , Maria Clara Teixeira Sento Sé, Livya Mackllaf Figueiredo Feitoza, Fernanda Fabian Callejon Cicilio , Ana Flávia Vieira Xavier, Kevin William Neves Lacerda, Raimundo Nogueira de Oliveira Júnior, João Victor Rego Dias Lima , Isnara de Sá Leitão Pinheiro de Gouveia, Filomeno Bastos de Mesquita Neto, Ayres Milano de Souza Neto, João Victor Vasconcelos Tavares Maximiliano, Gabriela Barbosa de Sá Rocha, Yves Cardoso Cavalcante, Vitor Lins Acioli Barreto, Eliab Batista Barros, Lorena Narel Ferreira Batista, Sabrina Maria Araujo Sobreira, Ariany de Assis Moura

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.



